A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2015

At a glance

  • Drugs Sotagliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 May 2015 Efficacy results correlated with urine sodium:creatinine ratio presented at the 30th Annual Scientific Meeting of the American Society of Hypertension.
    • 26 Sep 2013 Tolerability results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top